Compare RAMP & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | PVLA |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1994 | N/A |
| Metric | RAMP | PVLA |
|---|---|---|
| Price | $37.92 | $156.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $35.60 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 808.8K | 175.8K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22500.00 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $812,940,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | $104,350.18 |
| P/E Ratio | $135.04 | ★ N/A |
| Revenue Growth | ★ 9.03 | N/A |
| 52 Week Low | $21.71 | $44.25 |
| 52 Week High | $38.23 | $161.38 |
| Indicator | RAMP | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 57.45 |
| Support Level | $37.65 | $106.07 |
| Resistance Level | $37.91 | $159.98 |
| Average True Range (ATR) | 0.14 | 8.17 |
| MACD | -0.04 | 0.36 |
| Stochastic Oscillator | 68.42 | 80.14 |
LiveRamp Holdings Inc is a technology company that empowers marketers and media owners to deliver and measure marketing performance everywhere it matters. Its data collaboration network seamlessly unites data across advertisers, ad tech platforms, publishers, data providers, and commerce media networks, unlocking insights that deliver transformational consumer experiences and drive measurable business outcomes. The group's platform is engineered for AI agent accessibility, facilitating autonomous data collaboration between the specialized AI agents utilized by customers and partners and the networked platform. It generates the geographic revenue from the United States, followed by Europe, Asia-Pacific ("APAC"), and Other.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.